Project Grant R41CA268623
Award Date
5/1/22
Completion Date
4/30/24
Dollars Obligated
$1.6M
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Maryland, USA
Similar Awards
Morphogenesis, Inc. was awarded a $1,200,000 Project Grant from the National Cancer Institute, part of the Department of Health and Human Services, to develop a low-cost topical immunotherapy formulation suitable for treating cervical cancer in low- and middle-income countries and low-resource settings in the United States. The funding supports optimization of Morphogenesis' IFX-HU2.1 plasmid DNA-based cream formulation for temperature stability using established methods and models. In vitro...
The National Cancer Institute (NCI) awarded a $1,905,304 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to Washington University in St. Louis to conduct research on "Accelerated Brachytherapy Forward Chemoradiation Therapy (ABC-RT) for Cervical Cancer". The 5-year project, starting August 2024, aims to determine if an accelerated brachytherapy-forward chemoradiation therapy approach can safely shorten treatment time and maximize the anti-tumor immune response...
This Project Grant award from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) provides $367,472 to support the development of Gynion, LLC's ClaraBlex gel for the ablative treatment of cervical intraepithelial neoplasia (CIN), a precancerous condition caused by human papillomavirus (HPV) infection. The ClaraBlex gel, formulated with trichloroacetic acid, is designed to provide a simple, effective, and affordable point-of-care treatment that can be readily...
This $255,730 National Science Foundation project grant supports the development of self-assembling molecular brachytherapy for treatment of metastatic cancer. The goal is to enable radiation therapies for metastatic cancer, which accounts for approximately 90% of cancer deaths in the United States each year. The grantee, Oncurie, LLC, seeks to advance a radiotherapy approach that exploits cancer cells themselves as catalysts for therapeutic delivery. Specifically, the company will develop an...
The National Cancer Institute (NCI) awarded a $798,512 Project Grant under CFDA 93.395 - Cancer Treatment Research to Luminary Therapeutics, Inc., a small disadvantaged business, to develop an allogeneic gamma/delta armored dual-targeting chimeric antigen receptor (CAR) T-cell therapy to treat epithelial ovarian carcinoma. The project aims to address key challenges with CAR T-cell therapies against solid tumors, including antigen escape and the immunosuppressive tumor microenvironment, through...
The National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), awarded a $1,172,978 Phase II Small Business Innovation Research (SBIR) grant to Ananya Health Inc. to develop a portable, battery-powered, closed-loop cryotherapy system for the treatment of cervical precancerous lesions in low- and middle-income countries (LMICs). The key objectives of this 2-year project are to: 1) finalize the system design and verify it meets all requirements...
This $379,981 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to develop a localized cancer immunotherapy using particle-anchored cytokines for prolonged intratumoral retention. The primary objectives are to: (I) develop liposome-anchored cytokines with extended tumor retention and minimal systemic leakage, and (II) elucidate the mechanisms by which particle-anchored cytokines elicit durable anti-tumor immunity to improve efficacy in poorly...
This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $609,749 to the University of North Carolina at Chapel Hill to develop a novel combination therapy for the treatment of glioblastoma multiforme (GBM), the most aggressive form of brain cancer. The key products/services to be delivered include: Developing an injectable, biodegradable hydrogel scaffold that can accommodate high concentrations of induced neural stem cells...
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Phase I Small Business Technology Transfer (STTR) project grant, awarded to Vivosphere LLC, is developing a novel 3D tissue-engineered platform for cancer modeling and high-throughput drug screening. The $275,000 project aims to create a more physiologically relevant and scalable system to improve the translation of preclinical cancer drug candidates to clinical trials. Key objectives include testing...
This $399,499 Project Grant award from the National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), supports the development of Liquid Biotech's TELOMESCAN circulating tumor cell (CTC) assay for monitoring non-small cell lung cancer (NSCLC) patients undergoing radiation and immunotherapy. The key products and services to be delivered through this funding include: 1) Developing a clinical prototype of the TELOMESCAN assay with automated analysis to...